Search Results - joseph+barbi

3 Results

Sort By:

Neuritin Impact T Cell Tolerance Induction and Maintenance and is a Target for Tumor Immunotherapy

Unmet NeedCancer immunotherapy is a therapeutic approach that has revolutionized advanced cancer treatment. In particular, the use of therapeutic blocking antibodies to cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed cell death protein (PD-1) has achieved routine clinical use in numerous indications. Despite these promising results, monotherapy...

Published: 3/14/2025 | Inventor(s): Drew Pardoll, Hong Yu, Joseph Barbi, Fan Pan, Charles Drake

Keywords(s): Antibodies, Autoimmune Diseases, Biologics, Cancers, Combination, Disease Indication, Inflammatory Disorders, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Manipulation of Regulatory T Cell and DC Function by Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists

Unmet NeedThe recent breakthroughs in immuno-oncology have changed the way that researchers think about treating autoimmune diseases and cancer by modulating the immune system. Regulatory T cells (Treg) limit autoimmunity but also attenuate the potency of antitumor immunity. Enhancement of Treg function could treat autoimmune diseases while the inhibition...

Published: 3/13/2025 | Inventor(s): Drew Pardoll, Joseph Barbi, Fan Pan, Hong Yu, Ching-Tai Huang, Xiaoyu Pan, Charles Drake, Jonathan Powell

Keywords(s): Antibodies, Biologics, Cancers, Disease Indication, Immunotherapy, Infectious Diseases, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics

Targeting YAP Activity in Combination with Immunomodulation to Alter Regulatory T Cell-mediated Immune Regulation in order to Treat Cancer

TITLE: INHIBITION OF YAP FOR BREAKING TUMOR IMMUNE TOLERANCECASE NUMBER: C13353UNMET NEEDRegulatory T cells (Tregs) play critical roles in maintaining self-tolerance and homeostasis by suppressing the activation and function of other immune cells. At the same time, the immune-dampening effects of Tregs can inhibit the development...

Published: 3/13/2025 | Inventor(s): Benjamin Park, Drew Pardoll, Duojia Pan, Joseph Barbi, Fan Pan

Keywords(s): Biomarker, Cancers, Disease Indication, Mechanism-of-action Biomarker, Target, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities